206 related articles for article (PubMed ID: 9662266)
1. Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets.
Brubaker DB; Marcus C; Holmes E
Am J Hematol; 1998 Jul; 58(3):165-76. PubMed ID: 9662266
[TBL] [Abstract][Full Text] [Related]
2. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy of low and high dose prophylactic platelet transfusion therapy in thrombocytopenic haemato-oncology patients.
Dhiman Y; Hans R; Sharma RR; Malhotra P; Marwaha N
Transfus Apher Sci; 2020 Feb; 59(1):102610. PubMed ID: 31345687
[TBL] [Abstract][Full Text] [Related]
5. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution.
Davis KB; Slichter SJ; Corash L
Transfusion; 1999 Jun; 39(6):586-92. PubMed ID: 10378838
[TBL] [Abstract][Full Text] [Related]
6. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
8. An alloimmunized, thrombocytopenic patient successfully transfused with acid-treated, random-donor platelets.
Shanwell A; Sallander S; Olsson I; Gulliksson H; Pedajas I; Lerner R
Br J Haematol; 1991 Nov; 79(3):462-5. PubMed ID: 1751374
[TBL] [Abstract][Full Text] [Related]
9. Platelet corrected count increments by apheresis platform.
Tobian AA; King KE; Borge PD; Fuller AK; Uglik K; Ness PM
Transfusion; 2016 Oct; 56(10):2584-2586. PubMed ID: 27572682
[TBL] [Abstract][Full Text] [Related]
10. Effects of storage time on quantitative and qualitative platelet function after transfusion.
Rosenfeld BA; Herfel B; Faraday N; Fuller A; Braine H
Anesthesiology; 1995 Dec; 83(6):1167-72. PubMed ID: 8533908
[TBL] [Abstract][Full Text] [Related]
11. Correlation of platelet crossmatch results by Solid Phase Red Cell Adherence Assay (SPRCA) with post-transfusion platelet count increment in adult hemato-oncology patients of a tertiary care oncology centre in India.
Desai P; Sontakke P; Rajadhyaksha S; Navkudkar A
Transfus Apher Sci; 2020 Oct; 59(5):102842. PubMed ID: 32586771
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions.
Abraham AS; Chacko MP; Fouzia NA; Srivastava A; Daniel D
Transfus Med; 2018 Oct; 28(5):392-397. PubMed ID: 29460307
[TBL] [Abstract][Full Text] [Related]
13. Primary refractoriness to platelet transfusion caused by Nak(a) antibody alone.
Fujino H; Ohta K; Taniue J; Nagao N; Hino M; Yamane T; Koh KR; Takeoka Y; Hirose A; Aoyama Y; Nakamae H; Terada Y; Takubo T; Tatsumi N
Vox Sang; 2001 Jul; 81(1):42-4. PubMed ID: 11520415
[TBL] [Abstract][Full Text] [Related]
14. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing 20-hour increments after platelet transfusion.
Bishop JF; Matthews JP; McGrath K; Yuen K; Wolf MM; Szer J
Transfusion; 1991 Jun; 31(5):392-6. PubMed ID: 2048176
[TBL] [Abstract][Full Text] [Related]
16. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion.
Rinder HM; Murphy M; Mitchell JG; Stocks J; Ault KA; Hillman RS
Transfusion; 1991 Jun; 31(5):409-14. PubMed ID: 1710840
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of cross-match compatible platelets in multi transfused haemato-oncology patients refractory to platelet transfusion.
Chavan A; Sharma RR; Saikia B; Malhotra P; Prakash S; Hans R; Marwaha N
Transfus Apher Sci; 2019 Dec; 58(6):102657. PubMed ID: 31706911
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
Diedrich B; Ringdén O; Watz E; Shanwell A
Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
[TBL] [Abstract][Full Text] [Related]
20. Incubation of platelet concentrates before transfusion does not improve posttransfusion recovery.
Hussein MA; Schiffer CA; Lee EJ
Transfusion; 1990 Oct; 30(8):701-3. PubMed ID: 2219256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
